You are currently viewing a new version of our website. To view the old version click .

81 Results Found

  • Article
  • Open Access
3 Citations
5,617 Views
11 Pages

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance

  • Fabrizio Calapai,
  • Carmen Mannucci,
  • Mariaconcetta Currò,
  • Luigi Cardia,
  • Emanuela Esposito,
  • Gioacchino Calapai and
  • Ilaria Ammendolia

11 March 2024

Background: Evolocumab is a humanized immunoglobulin G2 monoclonal antibody, directed against Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), prescribed in hypercholesterolemic patients. The safety profile of this drug is currently defined by...

  • Article
  • Open Access
877 Views
20 Pages

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database

  • Pier Paolo Olimpieri,
  • Fanny Erika Palumbo,
  • Gaetano Giuffrida,
  • Edoardo Milanetti,
  • Cecilia Gozzo,
  • Elisa Lucia Scebba,
  • Giovanni Luca Romano,
  • Giovanni Enrico Lombardo,
  • Andrea Duminuco and
  • Calogero Vetro
  • + 5 authors

Background: Clinical trials comparing novel oral anticoagulants (NOACs) with warfarin reported a lower mortality rate and a reduced incidence of bleeding with NOACs. However, these studies do not allow for final conclusions about safety. Moreover, di...

  • Article
  • Open Access
1 Citations
2,690 Views
15 Pages

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance

  • Desirèe Speranza,
  • Fausto Omero,
  • Vincenzo Cianci,
  • Mariapia Marafioti,
  • Carla Infurna,
  • Patrizia Carroccio,
  • Edoardo Spina,
  • Maria Antonietta Barbieri,
  • Emanuela Esposito and
  • Nicola Silvestris
  • + 1 author

Background: Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-wor...

  • Article
  • Open Access
3 Citations
4,813 Views
18 Pages

Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database

  • Cristina Anamaria Buciuman,
  • Carmen Maximiliana Dobrea,
  • Anca Butuca,
  • Adina Frum,
  • Felicia Gabriela Gligor,
  • Octavia Gligor,
  • Laura Grațiela Vicaș and
  • Claudiu Morgovan

17 July 2025

Background: Ibuprofen is one of the most accessible non-steroidal anti-inflammatory drugs (NSADs), exhibiting non-selective reversible inhibition on COX-1 and COX-2. A series of common adverse reactions have been mentioned through the years: gastroin...

  • Article
  • Open Access
1 Citations
4,880 Views
17 Pages

Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance

  • Arturo Gómez López de las Huertas,
  • Stefan Stewart,
  • Mikel Urroz Elizalde,
  • Javier Guijarro-Eguinoa,
  • Enrique Seco-Meseguer,
  • Elena Diago-Sempere,
  • María Jiménez González,
  • Antonio J. Carcas-Sansuan,
  • Alberto M. Borobia Pérez and
  • Elena Ramírez

27 April 2025

Background/Objectives: Post-market surveillance of COVID-19 vaccines is vital. This study analyzed EudraVigilance data (Jan 2021–Dec 2023) to detect potential safety signals linking COVID-19 vaccines and specific neurological adverse events (as...

  • Article
  • Open Access
408 Views
14 Pages

26 November 2025

Background/Objectives: Bullous pemphigoid (BP) is an autoimmune blistering skin disease. The association between dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) and bullous pemphigoid (BP) has been studied in many countries; however, controversy...

  • Article
  • Open Access
4 Citations
3,132 Views
22 Pages

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance

  • Ioana Rada Popa Ilie,
  • Carmen Maximiliana Dobrea,
  • Anca Butuca,
  • Calin Homorodean,
  • Claudiu Morgovan,
  • Andreea Loredana Vonica-Tincu,
  • Felicia Gabriela Gligor,
  • Steliana Ghibu and
  • Adina Frum

4 December 2024

Background/Objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone. While it offers significant benefits as a second-line treatment for uncontrolled acromegal...

  • Article
  • Open Access
3 Citations
2,681 Views
15 Pages

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database

  • Concetta Rafaniello,
  • Valerio Liguori,
  • Alessia Zinzi,
  • Mario Gaio,
  • Angela Falco,
  • Luigi Di Costanzo,
  • Francesca Gargano,
  • Valentina Trimarco,
  • Mauro Cataldi and
  • Annalisa Capuano

During pre-approval clinical trials, the safety of axi-cel, a second-generation CAR-T-cell therapy directed against CD19, which dramatically improved the prognosis of intractable B-cell lymphomas, has been investigated only in about 400 patients. The...

  • Article
  • Open Access
1 Citations
3,367 Views
13 Pages

25 September 2024

Background: Intranasal corticosteroids (INCS) are used for several conditions, including allergic rhinitis and sinusitis. Consequently, their safety profile needs continuous monitoring. This study aimed to analyse the adverse drug reactions (ADRs) of...

  • Article
  • Open Access
3 Citations
3,088 Views
13 Pages

7 July 2023

Poly (ADP-Ribose) polymerase inhibitors (PARPi) have emerged as a targeted therapy in cancer treatment with promising results in various types of cancer. This work aims to investigate the profile of adverse drug reactions (ADRs) associated with PARPi...

  • Article
  • Open Access
23 Citations
8,500 Views
17 Pages

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance

  • Gabriela Pop,
  • Andreea Farcaș,
  • Anca Butucă,
  • Claudiu Morgovan,
  • Anca Maria Arseniu,
  • Manuela Pumnea,
  • Minodora Teodoru and
  • Felicia Gabriela Gligor

10 December 2022

Statins are included in the category of high-frequency prescription drugs, and their use is on an upward trend worldwide. In 2012, the FDA issued a warning about possible cognitive adverse drug reactions (ADRs) related to statins, some of which are l...

  • Article
  • Open Access
536 Views
18 Pages

Background: Medication safety in pregnancy, puerperium, and perinatal periods is underexplored because these populations are excluded from clinical trials. EudraVigilance offers post-marketing evidence, but disproportionality analyses focus on isolat...

  • Article
  • Open Access
6 Citations
2,059 Views
22 Pages

The Descriptive and Disproportionality Assessment of EudraVigilance Database Reports on Capecitabine Induced Cardiotoxicity

  • Razvan Constantin Vonica,
  • Anca Butuca,
  • Andreea Loredana Vonica-Tincu,
  • Claudiu Morgovan,
  • Manuela Pumnea,
  • Remus Calin Cipaian,
  • Razvan Ovidiu Curca,
  • Florina Batar,
  • Vlad Vornicu and
  • Adelaida Solomon
  • + 4 authors

16 November 2024

Capecitabine (CAP) is one of the most commonly prescribed fluoropyrimidines in oncology, especially in the treatment of colon cancer. Cardiac toxicity is a severe and potentially lethal adverse drug reaction (ADR) against fluoropyrimidines. Cardiac A...

  • Article
  • Open Access
7 Citations
8,808 Views
22 Pages

An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database

  • Anca Butuca,
  • Carmen Maximiliana Dobrea,
  • Anca Maria Arseniu,
  • Adina Frum,
  • Adriana Aurelia Chis,
  • Luca Liviu Rus,
  • Steliana Ghibu,
  • Anca Maria Juncan,
  • Andrei Catalin Muntean and
  • Antonina Evelina Lazăr
  • + 3 authors

Some glucagon-like peptide-1 receptor agonists (GLP-1 RAs), first used in the treatment of type 2 diabetes mellitus (T2DM), have been approved for the treatment of obesity in patients with or without T2DM (liraglutide—LIR, semaglutide—SEM...

  • Article
  • Open Access
355 Views
18 Pages

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database

  • Arianna Scala,
  • Teresa Angela Trunfio,
  • Chiara Pennisi,
  • Giovanni Enrico Lombardo,
  • Vincenzo Micale,
  • Serena Di Martino,
  • Giorgia Fiorenza,
  • Adriana Carol Eleonora Graziano,
  • Marilena Briglia and
  • Fabio Allia
  • + 11 authors

16 December 2025

Background/Objectives: Difficult-to-treat epileptic syndromes include conditions typically emerging in the first years of life and are characterized by a high rate of drug refractoriness. This study aimed to better define the safety profile of drugs...

  • Article
  • Open Access
18 Citations
4,029 Views
20 Pages

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database

  • Claudiu Morgovan,
  • Carmen Maximiliana Dobrea,
  • Adriana Aurelia Chis,
  • Anca Maria Juncan,
  • Anca Maria Arseniu,
  • Luca Liviu Rus,
  • Felicia Gabriela Gligor,
  • Simona Alexandrina Ardelean,
  • Laurentiu Stoicescu and
  • Steliana Ghibu
  • + 1 author

17 March 2023

Direct oral anticoagulant drugs (DOACs) interfere with the coagulation process, thus improving patient care for those who require anticoagulant treatment. This study presents a descriptive analysis of adverse reactions (ADRs) attributed to DOAC dosag...

  • Article
  • Open Access
1 Citations
2,326 Views
26 Pages

Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data

  • Paul Andrei Negru,
  • Delia Mirela Tit,
  • Andrei Flavius Radu,
  • Gabriela Bungau,
  • Raluca Anca Corb Aron and
  • Ruxandra Cristina Marin

Background/Objectives: During the COVID-19 pandemic, several antivirals were approved or repurposed, but their safety profiles have not been fully compared. Pharmacovigilance data help clarify how these drugs perform in real-world use. Methods: This...

  • Article
  • Open Access
10 Citations
5,420 Views
11 Pages

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database

  • Shruti Rastogi,
  • Vivekanandan Kalaiselvan,
  • Yousef A. Bin Jardan,
  • Saima Zameer and
  • Maryam Sarwat

21 February 2022

The primary prophylaxis with filgrastim (FIL) and pegfilgrastim (PEG-F) is recommended to decrease the severity of chemotherapy-induced neutropenia (CIN). The commonly reported adverse drug reactions (ADRs) with FIL and PEG-F is bone pain. ADRs perta...

  • Article
  • Open Access
2 Citations
1,736 Views
27 Pages

Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data

  • Aliteia-Maria Pacnejer,
  • Mihaela Cristina Negru,
  • Anca Maria Arseniu,
  • Cristina Trandafirescu,
  • Cristian Oancea,
  • Felicia Gabriela Gligor,
  • Claudiu Morgovan,
  • Anca Butuca and
  • Cristina Adriana Dehelean

11 March 2025

Remdesivir (RDV) and nirmatrelvir/ritonavir (NMVr) are among the most widely used antivirals in the treatment of COVID-19, aiming to reduce disease severity and progression. Adverse neuropsychiatric effects, such as anxiety, sleep disturbances, and m...

  • Article
  • Open Access
13 Citations
3,505 Views
13 Pages

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study

  • Alessia Zinzi,
  • Mario Gaio,
  • Valerio Liguori,
  • Rosanna Ruggiero,
  • Marina Tesorone,
  • Francesco Rossi,
  • Concetta Rafaniello and
  • Annalisa Capuano

9 February 2023

Although the safety profiles of mRNA COVID-19 vaccines (mRNA-1273 and BNT162b2) were evaluated in pre-authorization clinical trials, real-world data allow us to better define their benefit/risk ratio in the paediatric population. The current study ai...

  • Article
  • Open Access
10 Citations
3,259 Views
16 Pages

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units

  • Bogdan Ioan Vintila,
  • Anca Maria Arseniu,
  • Claudiu Morgovan,
  • Anca Butuca,
  • Mihai Sava,
  • Victoria Bîrluțiu,
  • Luca Liviu Rus,
  • Steliana Ghibu,
  • Alina Simona Bereanu and
  • Ioana Roxana Codru
  • + 1 author

9 November 2023

The Gram-positive anaerobic bacterium Clostridioides difficile (CD) can produce intense exotoxins, contributing to nosocomial infections, and it is the most common cause of health-care-associated infectious diarrhea. Based on spontaneous Individual C...

  • Article
  • Open Access
733 Views
17 Pages

Sex-Related Safety Signals of Sotorasib in Non-Small Cell Lung Cancer: A Real-World, Pharmacovigilance Study from the EudraVigilance Database

  • Desirèe Speranza,
  • Mariapia Marafioti,
  • Martina Musarra,
  • Vincenzo Cianci,
  • Fausto Omero,
  • Calogera Claudia Spagnolo,
  • Marco Calabrò,
  • Nicola Silvestris,
  • Natasha Irrera and
  • Mariacarmela Santarpia

19 October 2025

Background: Sotorasib, a KRAS G12C inhibitor, is approved for treating non-small cell lung cancer (NSCLC) and has shown a distinct safety profile in randomized clinical trials (RCTs). However, post-marketing pharmacovigilance is crucial to identify r...

  • Article
  • Open Access
12 Citations
3,069 Views
20 Pages

Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance

  • Claudiu Morgovan,
  • Carmen Maximiliana Dobrea,
  • Anca Butuca,
  • Anca Maria Arseniu,
  • Adina Frum,
  • Luca Liviu Rus,
  • Adriana Aurelia Chis,
  • Anca Maria Juncan,
  • Felicia Gabriela Gligor and
  • Cecilia Georgescu
  • + 2 authors

Trastuzumab (T) and tyrosine kinase inhibitors (TKIs) are among the first-line treatments recommended for HER2-positive breast cancer. More recently, antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-...

  • Article
  • Open Access
14 Citations
3,954 Views
12 Pages

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database

  • Fabrizio Calapai,
  • Ilaria Ammendolia,
  • Luigi Cardia,
  • Mariaconcetta Currò,
  • Gioacchino Calapai,
  • Emanuela Esposito and
  • Carmen Mannucci

Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis. The safety p...

  • Article
  • Open Access
2 Citations
2,200 Views
14 Pages

Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database

  • Jan Romantowski,
  • Wojciech Nazar,
  • Kinga Bojahr,
  • Iwona Popiołek and
  • Marek Niedoszytko

31 May 2024

Background: The coronavirus disease 2019 (COVID-19) pandemic presented a new challenge in modern medicine: the development of vaccines was followed by massive population vaccinations. A few reports on post-vaccination allergic reactions have made pat...

  • Article
  • Open Access
4 Citations
3,726 Views
15 Pages

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database

  • Giuseppe Cicala,
  • Michelangelo Rottura,
  • Viviana Maria Gianguzzo,
  • Federica Cristiano,
  • Selene Francesca Anna Drago,
  • Giovanni Pallio,
  • Natasha Irrera,
  • Egidio Imbalzano,
  • Edoardo Spina and
  • Vincenzo Arcoraci

12 October 2024

Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015...

  • Article
  • Open Access
5,922 Views
16 Pages

17 September 2025

Background: During the global fight against the COVID-19 pandemic, vaccinations have been widely recognized as the most effective and generally safe method for preventing the spread of COVID-19. However, it has been reported that children may experie...

  • Article
  • Open Access
3,570 Views
14 Pages

Hepatotoxicity and Antimicrobial Resistance to Amoxicillin and Amoxicillin/Clavulanic Acid: Data Analysis from EudraVigilance

  • Ilaria Ammendolia,
  • Carmen Mannucci,
  • Emanuela Esposito,
  • Gioacchino Calapai,
  • Mariaconcetta Currò,
  • Paola Midiri,
  • Luigi Cardia and
  • Fabrizio Calapai

21 September 2025

Amoxicillin is widely prescribed, either as a monotherapy or in combination with clavulanic acid, with its therapeutic indications including a broad range of infections. Its combination with clavulanic acid maintains its known activity against strain...

  • Article
  • Open Access
1,611 Views
12 Pages

Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database

  • Nunzia Balzano,
  • Annamaria Mascolo,
  • Raffaella Di Napoli,
  • Federica Colapietra,
  • Marina Di Domenico,
  • Annalisa Capuano and
  • Francesca Gargano

10 September 2024

Dexmedetomidine, a selective α2-adrenergic agonist, is favoured in intensive care for its minimal respiratory depression. This study evaluated the reporting frequency of rhabdomyolysis with dexmedetomidine compared to midazolam and propofol usi...

  • Article
  • Open Access
1 Citations
4,585 Views
16 Pages

Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis

  • Ilaria Ammendolia,
  • Carmen Mannucci,
  • Emanuela Esposito,
  • Gioacchino Calapai,
  • Mariaconcetta Currò,
  • Paola Midiri,
  • Cristina Mondello,
  • Luigi Cardia and
  • Fabrizio Calapai

Background/Objective: Major depressive disorder (MDD) is a common mental disorder, with a significant portion of patients developing treatment-resistant depression (TRD). Esketamine is an antagonist of the N-methyl-D-aspartate receptor indicated as a...

  • Article
  • Open Access
1 Citations
4,631 Views
25 Pages

Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005–2025)

  • Denisa Viola Szilagyi,
  • Delia Mirela Tit,
  • Claudia Teodora Judea-Pusta,
  • Andrei-Flavius Radu,
  • Gabriela S. Bungau,
  • Ada Radu,
  • Laura Maria Endres and
  • Ruxandra-Cristina Marin

24 August 2025

Background/Objectives: Isotretinoin is a highly effective therapy for severe acne, but its potential neuropsychiatric adverse reactions (NPsRs) have been controversial. This study evaluated EudraVigilance data from 2005 to 2025 to better understand t...

  • Article
  • Open Access
2,978 Views
17 Pages

13 December 2024

Background/Objectives: Vitamin D receptor (VDR) agonists are commonly used in clinical practice for their roles in calcium regulation and potential benefits in various diseases. However, their safety profiles, particularly for compounds available as...

  • Article
  • Open Access
8 Citations
3,003 Views
13 Pages

19 July 2023

In the last decades, the clinical management of oncology patients has been transformed by the introduction of biologics. The high costs associated with the development and production of biologics limit patient access to these therapies. The expiratio...

  • Article
  • Open Access
17 Citations
7,121 Views
11 Pages

17 January 2019

Paracetamol is a popular and easily available drug which is used world-wide as analgesic, antipyretic agent. Hypersensitivity reactions to this drug involve a wide range of symptoms of various importance for patient management. The EudraVigilance (EV...

  • Article
  • Open Access
81 Citations
17,594 Views
8 Pages

16 April 2021

The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early in December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European count...

  • Article
  • Open Access
1 Citations
4,421 Views
21 Pages

Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports

  • Cristina Anamaria Buciuman,
  • Carmen Maximiliana Dobrea,
  • Anca Butuca,
  • Adina Frum,
  • Felicia Gabriela Gligor,
  • Mihai O. Botea,
  • Laura Grațiela Vicaș,
  • Mariana Eugenia Mureșan,
  • Octavia Gligor and
  • Florin Maghiar
  • + 2 authors

29 August 2025

Background/Objectives: Mental health awareness is rising; thus, neurological and psychiatric side effects also benefit from increased attention from the medical and scientific community. Ibuprofen is a well-known non-steroidal anti-inflammatory drug...

  • Brief Report
  • Open Access
2 Citations
1,737 Views
11 Pages

Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)

  • Ilaria Ammendolia,
  • Maria Sframeli,
  • Emanuela Esposito,
  • Luigi Cardia,
  • Alberto Noto,
  • Mariaconcetta Currò,
  • Gioacchino Calapai,
  • Maria De Pasquale,
  • Carmen Mannucci and
  • Fabrizio Calapai

11 November 2024

Background/Objectives: Neuronal Ceroid Lipofuscinosis type 2 is a rare pathology affecting mainly the central nervous system (CNS) and retina, and is caused by variants in the gene encoding the lysosomal enzyme tripeptidyl peptidase 1. Therapy with e...

  • Article
  • Open Access
31 Citations
9,930 Views
16 Pages

The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process

  • Kamila Sienkiewicz,
  • Monika Burzyńska,
  • Izabela Rydlewska-Liszkowska,
  • Jacek Sienkiewicz and
  • Ewelina Gaszyńska

All medicinal products authorized in the European Union are subjects of constant drug-safety monitoring processes. It is organized in a pharmacovigilance system that is designed to protect human health and life by the detection, analysis and preventi...

  • Article
  • Open Access
3 Citations
2,025 Views
17 Pages

28 February 2025

Background: The advent of biosimilars has revolutionized the management of conditions like rheumatoid arthritis by offering cost-effective alternatives to expensive biologics. Objectives: This study aims to compare the post-marketing safety profiles...

  • Article
  • Open Access
1 Citations
1,382 Views
11 Pages

Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance

  • Andrej Belančić,
  • Petar Mas,
  • Lara Miletić,
  • Barbara Kovačić Bytyqi and
  • Dinko Vitezić

Background/Objectives: Spinal muscular atrophy (SMA) treatment has evolved with the approval of nusinersen, onasemnogene abeparvovec, and risdiplam. This study aims to assess the post-marketing safety profile of these therapies through the spontaneou...

  • Article
  • Open Access
2 Citations
1,847 Views
22 Pages

Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment

  • Razvan Constantin Vonica,
  • Anca Butuca,
  • Claudiu Morgovan,
  • Manuela Pumnea,
  • Remus Calin Cipaian,
  • Adina Frum,
  • Carmen Maximiliana Dobrea,
  • Andreea Loredana Vonica-Tincu,
  • Aliteia-Maria Pacnejer and
  • Steliana Ghibu
  • + 2 authors

30 March 2025

Background/Objectives: Worldwide, colon cancer is a major cause of cancer-related mortality, with an increasing incidence influenced by genetic, environmental, and lifestyle factors. Despite advances in diagnosis and personalized treatments, challeng...

  • Article
  • Open Access
6 Citations
8,043 Views
16 Pages

Drug–Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database

  • Carmen Maximiliana Dobrea,
  • Adina Frum,
  • Anca Butuca,
  • Claudiu Morgovan,
  • Laurentiu Stoicescu,
  • Adriana Aurelia Chis,
  • Anca Maria Arseniu,
  • Luca Liviu Rus,
  • Felicia Gabriela Gligor and
  • Andreea Loredana Vonica-Tincu

26 September 2024

As the most common psychiatric symptom, depression represents a subject of high interest for the medical community. Background/Objectives: International guidelines consider selective serotonin reuptake inhibitors (SSRIs) the first-line treatment of d...

  • Article
  • Open Access
7 Citations
2,797 Views
17 Pages

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database

  • Liberata Sportiello,
  • Raffaella Di Napoli,
  • Nunzia Balzano,
  • Annamaria Mascolo,
  • Rosanna Ruggiero,
  • Luigi Di Costanzo,
  • Davida Monaco,
  • Giorgia Teresa Maniscalco and
  • Annalisa Capuano

6 November 2023

(1) Background: The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS). (2) Methods: Individual case safety reports (ICSRs...

  • Article
  • Open Access
6 Citations
5,041 Views
12 Pages

Descriptive Analysis of Adverse Drug Reactions Reports of the Most Consumed Antibiotics in Portugal, Prescribed for Upper Airway Infections

  • Joana Ferreira,
  • Ana Isabel Placido,
  • Vera Afreixo,
  • Inês Ribeiro-Vaz,
  • Fátima Roque and
  • Maria Teresa Herdeiro

Adverse drug reactions (ADR) significantly impact mortality and morbidity and lead to high healthcare costs. Reporting ADR to regulatory authorities allows for monitoring the safety and efficacy profile of medicines on the market and for assessing th...

  • Article
  • Open Access
1 Citations
2,578 Views
20 Pages

Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database

  • Ioana Rada Popa Ilie,
  • Andreea Loredana Vonica-Tincu,
  • Carmen Maximiliana Dobrea,
  • Anca Butuca,
  • Adina Frum,
  • Claudiu Morgovan,
  • Felicia Gabriela Gligor and
  • Steliana Ghibu

Insulin is essential for treating type 1 diabetes and insulin-requiring type 2 diabetes. Background/Objectives: Diabetes is a widespread condition that can lead to multiple and severe complications. Rapid-acting insulin analogs (RAIAs) and long-actin...

  • Article
  • Open Access
2 Citations
3,176 Views
16 Pages

The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug–Drug Interaction Insights from EudraVigilance

  • Carmen Maximiliana Dobrea,
  • Claudiu Morgovan,
  • Adina Frum,
  • Anca Butuca,
  • Adriana Aurelia Chis,
  • Anca Maria Arseniu,
  • Steliana Ghibu,
  • Razvan Constantin Vonica,
  • Felicia Gabriela Gligor and
  • Ioana Rada Popa Ilie
  • + 1 author

12 February 2025

Depression persists as one of the illnesses described relentlessly through the centuries because it affects a large group of people. Background/Objectives: The treatment of depression consists of various therapeutic agents, among which selective sero...

  • Article
  • Open Access
18 Citations
4,449 Views
17 Pages

Adverse Drug Reactions Relevant to Drug Resistance and Ineffectiveness Associated with Meropenem, Linezolid, and Colistin: An Analysis Based on Spontaneous Reports from the European Pharmacovigilance Database

  • Bogdan Ioan Vintila,
  • Anca Maria Arseniu,
  • Anca Butuca,
  • Mihai Sava,
  • Victoria Bîrluțiu,
  • Luca Liviu Rus,
  • Dan Damian Axente,
  • Claudiu Morgovan and
  • Felicia Gabriela Gligor

Antimicrobial resistance is considered one of the major threats to public health and is an important factor that influences the patient’s outcome in the intensive care unit. Pharmacovigilance can help raise awareness of potential drug resistanc...

  • Article
  • Open Access
38 Citations
8,053 Views
8 Pages

15 November 2021

Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the...

  • Article
  • Open Access
6 Citations
3,272 Views
13 Pages

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

  • Vera Martins,
  • Mafalda Jesus,
  • Luísa Pereira,
  • Cristina Monteiro,
  • Ana Paula Duarte and
  • Manuel Morgado

22 September 2023

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palboc...

  • Article
  • Open Access
5 Citations
6,155 Views
14 Pages

COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database

  • Rosanna Ruggiero,
  • Maria Donniacuo,
  • Annamaria Mascolo,
  • Mario Gaio,
  • Donato Cappetta,
  • Concetta Rafaniello,
  • Giovanni Docimo,
  • Consiglia Riccardi,
  • Imma Izzo and
  • Donatella Ruggiero
  • + 4 authors

Atrial fibrillation (AF) has been described in COVID-19 patients. Recently, some case reports and US pharmacovigilance analyses described AF onset as a rare adverse event following COVID-19 vaccination. The possible correlation is unclear. We systema...

of 2